Skip to main content

Advertisement

SpringerLink
Log in

Clozapine: A Clinical Review of Adverse Effects and Management

  • Published:
Annals of Clinical Psychiatry

Abstract

Clozapine (Clozaril®) is a novel and unique prototype atypical, tricyclic, dibenzodiazepine-derivative, antipsychotic agent. It has been proven effective and significantly superior to placebo, as well as to conventional neuroleptics, in several placebo-controlled, double-blind studies in treatment-resistant schizophrenia. It has also been found to produce an incidence of extrapyramidal symptoms (EPS) as low as that found with placebo. Approximately 30–60% of all schizophrenic patients who fail to respond to typical antipsychotics may respond to clozapine. It was the first major advance that marked a turning point in the treatment of schizophrenia and other psychotic disorders since the introduction of the typical antipsychotic agents, i.e., chlorpromazine and haloperidol in the 1950s and 1960s, respectively. After its introduction in clinical studies in the United States in the early 1970s, it was withdrawn in 1974, and was not approved for clinical use in the United States until February 1990, because of the risk of agranulocytosis. Its novel pharmacological profile, lack of propensity to cause EPS in both short- and long-term uses, lack of effects on serum prolactin, and ameliorative effects on tardive dyskinesia have resulted in the expansion of its use from refractory schizophrenia to schizoaffective disorders, affective disorders, some neurological disorders, aggression, as well as psychosis in patients with dementia and parkinsonism. This review covers the history, pharmacology, management of side effects, and fetal and neonatal effects of clozapine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19

    Google Scholar 

  2. Rosentein MJ, Milazzo-Sayre LJ, Manderscheid RW: Care of persons with schizophrenia: A statistical profile. Schizophr Bull 1989; 15:45-58

    Google Scholar 

  3. Feltus MS, Gardner DM: Second generation antipsychotics for schizophrenia. Can J Clin Pharmacology 1999; 6:187-195

    Google Scholar 

  4. Bartell PJ, Donenwirth K, et al.: Violence and schizophrenia: Clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995; 23:607-611

    Google Scholar 

  5. Cohen SA, Underwood MT: The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994; 55:440-444

    Google Scholar 

  6. Gilman AG, Ruddon RW, Molinoff PB, Limberd LE, Hardman JG: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Health Professions Division; 1996

    Google Scholar 

  7. Antipsychotic Agents: In: Baldessarini RJ, ed.: Chemotherapy in Psychiatry: Principles & Practice. Cambridge, MA: Harvard University Press, 1985:14-92

    Google Scholar 

  8. Hunziker F, Kunzte F, Schmutz J: Uben ein 5-Stellung basisch substituiente 5H Dibenzo (b,e)-1–4 diazepine. Helv Chim Acta 1963; 46:2337-2347

    Google Scholar 

  9. Hippius H: The history of clozapine. Psychopharmacology. 1989; 99:S3-S5

    Google Scholar 

  10. Nightingle SL: Approval of clozapine for refractory schizophrenia. JAMA 1990: 263:202

    Google Scholar 

  11. Richelson E, Elson A: Antagonism of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984; 103:197-214

    Google Scholar 

  12. Waddington JL: Neuroleptic/dopamine receptors. Eur J Pharmacol 1990; 183:106

    Google Scholar 

  13. Meltzer HR, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of D1-D2 and serotonin, PK1 values. J Pharmacol Exp Ther 1989; 251:3238-3246

    Google Scholar 

  14. Picker D, Owen RR, Litran RE, Konicki PE, Gutiennez R, Rappaport HM: Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353

    Google Scholar 

  15. Litran RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D: Idazoxan, an alpha2 antagonist, augments fluphenazine in schizophrenic patients. A pilot study. J Clin Psychopharmacol 1993; 13:264-267

    Google Scholar 

  16. Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical antipsychotics: Part II–Adverse effects, drug interactions and costs. Ann Pharmacother 1999 33:210-217

    Google Scholar 

  17. Choe MG, Hsuan F, Honigfeld G, et al.: Single vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmacol Res. 1990; 7:347-351

    Google Scholar 

  18. Tandon R: Antipsychotic agents. In: Quitkin FM, Adams DC, Bowden CL, Heyer EJ, Rifkin A, Sellers EM, Tandon R, Taylor BP: eds. Current Psychotherapeutic Drugs, 2nd edn. Philadelphia: Current Medicine; 1998

    Google Scholar 

  19. Sajatovic M: Clozapine for elderly patients. Pychiatric Ann. 2000; 30(3):170-174

    Google Scholar 

  20. Kim BB: The Medical Letter Handbook of Adverse Drug Interactions. New York: The MedicalLetter; 2001: 206-209

    Google Scholar 

  21. Young CR, Bowers, MB, Jr., Mazure CM: Management of the adverse effects of clozapine. Schizophr Bull 1998; 24(3): 381-390

    Google Scholar 

  22. Gerson SL: G-CSF and the management of clozapine induced agranulocytosis. J Clin Psychiatry 1994; 55(Suppl B):139-142

    Google Scholar 

  23. Lieberman JA, Yunis J, Egen E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine induced agranulocytosis. Arch Gen Psychiatry 1990; 47:945-948

    Google Scholar 

  24. Alvir JM, Lieberman JA: Agranulocytosis: Incidence and risk factors. J Clin Psychiatry 1994; 55(Suppl B):137-138

    Google Scholar 

  25. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis—Incidence and risk factors in the United States. N Eng J Med 1993; 329:162-167

    Google Scholar 

  26. Lieberman JA, Kane JM, and Johns CA: Clozapine: Guidelines for clinical management. J Clin Psychiatry 1989; 50:329-338

    Google Scholar 

  27. Lieberman JA, Safferman AZ. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr Q 1992; 63:51-70

    Google Scholar 

  28. Lieberman JA: Maximizing clozapine therapy: Managing side effects. J Clin Psychiatry. 1998; 59 (Suppl 3): 38-43

    Google Scholar 

  29. Honingfeld G, Arellano F, Sethi J, Bianchini A, Schein J: Reducing clozapine-related morbidity and mortality: 5 years experience with the Clozaril National Registry [Abstract]. J Clin Psychiatry 1998; 59(Supp1) 3:3-7

    Google Scholar 

  30. Silver JM, Yudofsky SC, Jurowitz GI: Psychopharmacology and electroconvulsive therapy. In: Hales RE, Yudofsky SC, Talbott JA, ed., The American Psychiatric Press Textbook of Psychiatry 2nd edn. Washington, DC. American Psychiatric Press, 1994: p. 920

    Google Scholar 

  31. Krupp P, Barnes P: Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology 1989; 99:S118-S121

    Google Scholar 

  32. Bastani B, Alphs LD, Meltzer HY. Development of the Clozaril Patinet Management System [Abstract]. Psychopharmacology 1989; 99(Supp1):S122-S125

    Google Scholar 

  33. Friedberg JW, Frankenburg FR, Burk J, Johnson W: Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry 1995; 7:97-98

    Google Scholar 

  34. Chatterton R: Eosinophilia after commencement of clozapine treatment. Aust NZ J Psychiatry 1997; 31:874-876

    Google Scholar 

  35. Tihonen J, Paanila J: Eosinophilia associated with clozapine. Lancet 1992; 399:488

    Google Scholar 

  36. Banov MD, Tohen M, Friedberg J: High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54:466-469

    Google Scholar 

  37. Barbui C, Campomori A, Bonati M: Clozapine and blood dyscrasias different from agranulocytosis [Letter]. Can J Psychiatry 1997; 42(9):981-982

    Google Scholar 

  38. Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 1994; 55(9, Supp1 B): 153-156

    Google Scholar 

  39. Hill D: The relationship between schizophrenia and epilepsy. Folia Psychiat Neurol Neurochir 1948; 51:95-111

    Google Scholar 

  40. Notkin J: Epileptic manifestations in the group of schizophrenic and manic–depressive psychoses. J Nerv Ment Dis 1929; 69:494-521

    Google Scholar 

  41. Toth P, Frankenburg FR: Clozapine and seizures: A review. Can J Psychiatry 1994; 39:236-238

    Google Scholar 

  42. Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 1992; 41:369-371

    Google Scholar 

  43. Helwick CA: Review of clozapine therapy finds more ADRs than expected. Pharmacy Practice News 1992; March 1, p. 7

  44. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796

    Google Scholar 

  45. Claghorn J, Honigfeld G, Abuzzahab GS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384

    Google Scholar 

  46. Schmauss M, Wolff R, Erfurth A, Ruther E: Tolerability of long term clozaril treatment. Psychopharmacology (Berl) 1989; 99:S105-S108

    Google Scholar 

  47. Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 1990; 147:1069-1071

    Google Scholar 

  48. Itil TM, Soldatos C: Epileptogenic side-effects of psychotropic drugs: Practical recommendations. JAMA 1980; 244:1460-1463

    Google Scholar 

  49. Karper LP, Salloway SP, Seibyl JP, et al.: Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992; 4:454-457

    Google Scholar 

  50. Liukkonen J, Koponen HJ, Nousiainen U: Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment. Psychiatry Res 1992; 44:107-112

    Google Scholar 

  51. Gouzoulis E, Grunze H, Bardeleben UV: Myoclonic epileptic seizures during clozapine treatment: A report of three cases. Eur Arch Psychiatry Neurol Sci 1991; 240:370-372

    Google Scholar 

  52. Gouzoulis E, Ozdaglar A, Kasper J: Myoclonic seizures followed by grand mal seizures during clozapine treatment [Letter]. Am J Psychiatry 1993; 150:1128

    Google Scholar 

  53. Tiihonen J, Nousiainen U, Hakola P, Leinonen E, Tuunainen A, Mervalla E, Paanila J: EEG abnormalities associated with clozapine treatment [Letter]. Am J Psychiatry 1991; 148:1406

    Google Scholar 

  54. Isermann H, Haupt R: Auffallige EEG-Veranderungen unter Clozapin-Behandlung bei paranoid-halluzinatorischen. Psychosen Nervenarzt 1976; 47:268

    Google Scholar 

  55. Baldessarini RJ, Frankenburg FR: Clozapine: A novel antipsychotic agent. New Engl J Med 1991; 324:746-754

    Google Scholar 

  56. Kugler J, Lorenzi E, Spatz R, et al.: Drug-induced paroxysmal EEG activities. Pharmacopsychiatry 1979; 12:165-172

    Google Scholar 

  57. Roubicek J, Major I: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatry 1977; 12:613-633

    Google Scholar 

  58. Malow BA, Reese KB, Sato S, Bogard PJ, Malhotra AK, Su TP, Pickar D: Clozapine, myoclonus, and EEG abnormalities [Abstract]. Epilepsia 1993; 34(Supp1 6):129

    Google Scholar 

  59. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; 99(Suppl 99):S97-S100

    Google Scholar 

  60. Szymanski S, Jody D, Leipsig R, Masiar S, Lieberman N: Anticholinergic delirium caused by retreatment with clozapine [Letter]. Am J Psychiatry 1992; 148:1752

    Google Scholar 

  61. Schuster P, Gabriel E, Kufferle B, Strobl G, Karobuth M: Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10:437-441

    Google Scholar 

  62. Stanilla JK, Leon J, Simpson GM: Clozapine withdrawal resulting in delirium with psychosis: A report of three cases. J Clin Psychiatry 1997; 58(6):252-255

    Google Scholar 

  63. Simpson GM, Varga E: Clozapine: A new antipsychotic agent. Curr Therapeut Res 1974; 16:679-686

    Google Scholar 

  64. Simpson GM, Lee JH, Shrivastava RK: Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56:75-80

    Google Scholar 

  65. Panteleeva GP, Tsutsul Kovskaya MY, Belyaev BS, et al.: Clozapine in the treatment of schizophrenic patients; An international multi-center trial. Clin Ther 1987; 10:57-68

    Google Scholar 

  66. Juul Povlsen U, Noring U, Fog R: Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71:176-185

    Google Scholar 

  67. Safferman AZ, Lieberman AJ, Kane JM: Syzmanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17(2):247-261

    Google Scholar 

  68. Cohen S: Sedation: In: Yesavage J, ed. Clozapine: A Compendium of Selected Readings. Stanford CA: Sandoz Pharmaceutical; 1992: 132-133

    Google Scholar 

  69. Burke M, Sebastian CS: Treatment of clozapine sedation [Letter]. Am J Psychiatry 1993; 150:127

    Google Scholar 

  70. Meltzer HY: Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995: 631-639

    Google Scholar 

  71. Baker RW, Chengappa KN, Baird JW, Steingard MD, Christ MA, Schooler NR: Emergence of obsessive–compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992; 53(12):439-442

    Google Scholar 

  72. Levkovitch Y, Kronnenberg Y, Gaoni B: Can clozapine trigger OCD? [Letter]. J Am Acad of Child Adolesc Psychiatry 1995; 34(3):263

    Google Scholar 

  73. Cassidy SL, Thaker GK: Addition of fluoxetine to clozapine. Am J Psychiatry 1993; 149:1900-1901

    Google Scholar 

  74. Patel B, Tendon R: Development of obsessive–compulsive symptoms during clozapine treatment [Letter]. Am J Psychiatry 1993; 150(5):836

    Google Scholar 

  75. Tsai G, Cristomo G, Rosenblatt ML, Stern TA: Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91-95

    Google Scholar 

  76. Pope HG Jr, Cole JO, Choras PT Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 177(8):493-495

    Google Scholar 

  77. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Ann Pharmacother 1999; 33:623-630

    Google Scholar 

  78. Campellone JV, McCluskey LF, Greenspan D: Fatal outcome from neuroleptic malignant syndrome associated with clozapine. Neuropsychiatry Neuropsychol Behav Neurol 1995; 8:70-73

    Google Scholar 

  79. Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155(8):1113-1116

    Google Scholar 

  80. Sachdev P, Kurk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. J Clin Psychopharmacol 1995; 15(5):365-371

    Google Scholar 

  81. Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:717-725

    Google Scholar 

  82. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clinic North Am 1993; 77:185-202

    Google Scholar 

  83. Yamawaki S, Morio M, Kazamatsuri G, et al.: Clinical evaluation and effective usage of dantrolente sodium in neuroleptic malignant syndrome. Kiso to Rinsyou (Clinical Reports). 1993; 27:1045-1066

    Google Scholar 

  84. Fricchione G, Bush G, Fosdar M, et al.: Recognition and treatment of the catatonic syndrome. J Intensive Care Med 1997; 12:135-147

    Google Scholar 

  85. Scheftner WA, Shulman RB: Treatment choice in neuroleptic malignant syndrome. Convul Ther 1992; 8:267-279

    Google Scholar 

  86. Marinkovic D, Timtijevic I, Babinski T, Totic S, Paunovic VR: The side-effects of clozapine: A four year follow-up study. Prog Neuropsychopharmacol 1994; 18:537-544

    Google Scholar 

  87. Cohen BM, Keck PE, Satlin A, Cole JO: Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29:1215-1219

    Google Scholar 

  88. Safferman AZ, Lieberman JA, Pollack S, Kane JM: Akathisia and clozapine treatment [Letter]. J Clin Psychopharmacol 1993; 13:286-287

    Google Scholar 

  89. Wirshing WC, Phelan CK, Van Putten T, Marder SR, Engel J: Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia [Letter]. J Clin Psychopharmacol 1990; 10:371-373

    Google Scholar 

  90. Levin H, Chengappa KNR, Kambhamati RK, Mahdavi N, Ganguli R: Should treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53:248-251

    Google Scholar 

  91. Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM: Myoclonus in patients treated with clozapine: A case series. J Clin Psychiatry 1995; 56:418-422

    Google Scholar 

  92. Berman I, Zalma A, Durand CJ, Green AI: Clozapine-induced myoclonic jerks and drop attack [Letter]. J Clin Psychiatry 1992; 53:329-330

    Google Scholar 

  93. Meltzer HY, Ranjan R: Valproic acid treatment of clozapine-induced myoclonus [Letter]. Am J Psychiatry 1994; 151:1246-1247

    Google Scholar 

  94. Kilian JG, Kerr K, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845

    Google Scholar 

  95. Lilleng P, Morild I, Hope M: Clozapine and myocarditis. Tidsskr Nor Laegeforen 1995; 115:293-294

    Google Scholar 

  96. Meeker JE, Herrmann PW, Som CW, Reynolds PC: Clozapine tissue concentrations following an apparent overdose of clozaril. J Anal Toxicol 1992; 16:54-56

    Google Scholar 

  97. Jensen VE, Gotzsche O: Allergic myocarditis in clozapine treatment. Ugeskr Laeger 1994; 156:4151-4152

    Google Scholar 

  98. Khalil N: Peri/myocarditis with clozapine (leponex). Psychiatr Prax 1997; 24:46

    Google Scholar 

  99. Bandelow B, Degner D, Kreusch U, Ruther E: Myocarditis under therapy with clozapine. Schizophr Res 1995; 17:293-294

    Google Scholar 

  100. Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997; 8:671-677

    Google Scholar 

  101. Leo RJ, Kreeger JL, Kim KY: Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30:603-605

    Google Scholar 

  102. Hagg S, Spigset O, Soderstrom TG: Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155-1156

    Google Scholar 

  103. Wolstein J, Grohmann R, Ruther E, Hippius H: Antipsychotic drugs and venous thromboembolism [Correspondence]. Lancet 2000; 356:252

    Google Scholar 

  104. Knudson JF, Kortepeter C, Debitsky GM, Ahmad SR, Chen M: Antipsychotic drugs and venous thromboemolism [Correspondence]. Lancet 2000; 356:252-253

    Google Scholar 

  105. Cleophas TJM, Kauw FHW: Pressor responses from noncardioselective beta-blockers. Angiology 1988; 39:587-596

    Google Scholar 

  106. Testani M: Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55:497-498

    Google Scholar 

  107. Patterson TS: In: Yesavage J, ed: Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceuticals; 1992:136-138

    Google Scholar 

  108. Thulesius O, Berlin E: Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. Int J Clin Ther Toxicol 1986; 24:465-467

    Google Scholar 

  109. Rechlin T, Claus D, Weis M: Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994; 35:888-892

    Google Scholar 

  110. Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: An atypical antipsychotic agent. Clin Pharmacol 1989; 8:691-709

    Google Scholar 

  111. Casey D: Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 (Suppl 11):40-45

    Google Scholar 

  112. Wetterling T: Body weight gain with atypical antipsychotics—A comparative review. Drug Saf 2001; 24(1):59-73

    Google Scholar 

  113. Wirshing DA, Wirshing WC, Kysar L, Berisfor MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6):358-363

    Google Scholar 

  114. Bustillo JR, Buchanan RW, Irish D, Breir A: Differential effect of clozapine on weight: A controlled study. Am J Psychiatry 1996; 153(6): 817-819

    Google Scholar 

  115. Leadbetter R, Shutty M, Pavalonis D, Vieeg V, Higgins P, Downs M: Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149(1):68-72

    Google Scholar 

  116. Hummer M, Kemmler G, Kurz M, et al.: Weight gain induced by clozapine. Euro Neuropsychopharmacol 1995; 5:437-440

    Google Scholar 

  117. Breefa D, Meehan T: Weight changes during clozapine treatment. Aust NZ J Psychiatry 1998; 32(5):718-721

    Google Scholar 

  118. Wetterling T, Mussigbrodt HE: Weight gain: Side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19(4): 316-321

    Google Scholar 

  119. Kraus T, Haack M, Schuld A, Scleh DH, Kuhn M, Uhp M, Polluacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156(2):312-314

    Google Scholar 

  120. George TP, Sernyak MJ, Ziedonis DM, Woods SW: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56(8):344-346

    Google Scholar 

  121. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997

    Google Scholar 

  122. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain J Clin Psychiatry 1994; 55(Suppl B) S157-S160

    Google Scholar 

  123. Willet WC, Manson JE, Stampler MJ, Colditz GA, Rosner B, Speizer FE, Hennekers CH: Weight, weight change, and coronary heart disease in women: Risk within the ‘normal’ weight range. JAMA 1995; 273: 461-465

    Google Scholar 

  124. Fenton WS, Blyler CF, Heinssen PK: Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997; 23: 637-651

    Google Scholar 

  125. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-783

    Google Scholar 

  126. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V: Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagons in the rat. Neuroendocrinology 1996; 63:269-274

    Google Scholar 

  127. Wozniak KM, Linnoila M: Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991; 49:101-109

    Google Scholar 

  128. Hayes G, Gibler B: Clozapine-induced constipation [Letter]. Am J Psychiatry 1998; 152:298

    Google Scholar 

  129. Lennard-Jones JE: Clinical management of constipation. Pharmacology 1993; 47:216-223

    Google Scholar 

  130. Bourgeois JA, Drexler KG, Hall MJ: Hypersalivation and clozapine [Letter].. Hos Comm Psychiatry 1991; 42:1174

    Google Scholar 

  131. Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacodynamics and pharmacokinetics of clozapine. Clinl Pharmacokinet 1993; 24:161-176

    Google Scholar 

  132. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW: Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997; 17(4):314-317

    Google Scholar 

  133. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; (Suppl 99):S97-S100

  134. Kellner M, Wiedermann K, Krieg JC, Berg PA: Toxic hepatitis by clozapine treatment [Letter]. Am J Psychiatry 1993; 150:985-986

    Google Scholar 

  135. Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brosen K: Clozapine-induced toxic hepatitis. Ugeskrift for Laeger 2001; 163(14):2013-2014. (In Danish)

    Google Scholar 

  136. Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR: Hepatitis, hyperglycemia, pleural effesion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13(2):95-98

    Google Scholar 

  137. Dystonia and drug-induced hepatitis in a patient treated with clozapine [Letter]. Am J Psychiatry 1995; 152(4):647-648

  138. Thatcher GW, Cates M, Bair B: Clozaine-induced toxic hepatitis [Letter]. Am J Psychiatry 1995; 152(2):296-297

    Google Scholar 

  139. Sepulveda VAC, Lopez AE, Yanez LP, Ramirez CR, Escobar PB, Madrazo DGA: Sodium diphenylhydantoin as a probable cause of pancreatitis. Rev Gastroenterol Mex 1999; 64(4):186-189. (In Spanish)

    Google Scholar 

  140. Bergemann N, Ehrig C, Diebold K, Mundt C, von Einsiedel R: Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32(2):78-80

    Google Scholar 

  141. Jubert P: Clozapine-related pancreatitis [Letter]. Ann Intern Med 1994; 121(9):722-723

    Google Scholar 

  142. Martin A: Acute pancreatitis associated with clozapine use [Letter]. Am J Psychiatry 1992; 149:714

    Google Scholar 

  143. Frankenburg FR, Kando J: Eosinophilia, clozapine and pancreatitis [Letter]. Lancet 1992; 340:251

    Google Scholar 

  144. Davydov Liya, Botts SR: Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34:662-665

    Google Scholar 

  145. Robinson D, Fenn H, Yesavage J: Possible association of parotitis with clozapine. Am J Psychiatry 1995; 152:297-298

    Google Scholar 

  146. Brodkin ES, Pelton GH, Price LH: Treatment of clozapine-induced parotid gland swelling [Letter]. Am J Psychiatry 1996; 153:445

    Google Scholar 

  147. Vasile JS, Steingard S: Clozapine and the development of salivary gland swelling: A case study. J Clin Psychiatry 1995; 56:511-513

    Google Scholar 

  148. Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M: Aspiration pneumonia possibly secondary to clonzapine-induced sialorrhea [Letter]. J Clin Psychopharmacol 1996; 16:462-463

    Google Scholar 

  149. Zorn SH, Jones SB, Ward KM, Liston DR: Clozapine is a potent and selective muscrinic M4 receptor agonist. Eur J Pharmacol 1994; 269:R1-R2

    Google Scholar 

  150. Szabadi E: Clozapine-induced hypersalivation [Letter]. Br J Psychiatry. 1997; 171:89

    Google Scholar 

  151. Berlan M, Montastruc J-M, Lafontan M: Pharmacological prospects for alpha2-adrenoceptor antagonist therapy. Trends Pharmocol Sci 1992; 13:277-282

    Google Scholar 

  152. Pearlmen C. Clozapine, nocturnal sialorrhea, and chocking [Letter]. J Clin Psychopharmacol 1992; 12:69-70

    Google Scholar 

  153. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A: Trihexiphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmocol 1997; 12:213-215

    Google Scholar 

  154. Copp PJ, Lament R, Tennent TG: Amitriptyline in clozapine-induced sialorrhea [Letter]. Br J Psychiatry 1991; 159:166

    Google Scholar 

  155. Grabowski J: Clonidine treatment of clozapine-induced hypersalivation [Letter]. J Clin Psychopharmacol 1992; 12:69-70

    Google Scholar 

  156. Corrigan FM, MacDonald S, Reynolds GP: Clozapine-induced hypersalivation and the alpha2-adrenoceptor [Letter]. Br J Psychiatry 1995; 167:412

    Google Scholar 

  157. Aronowitz JS, Safferman AZ, Lieberman JA: Management of clozapine induced enuresis [Letter]. Am J Psychiatry 1995; 152:472

    Google Scholar 

  158. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE: Clozapine-induced urinary incontinence: Incidence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514-518

    Google Scholar 

  159. Steingard S: Use of desmopressin to treat clozapine-induced enuresis [Letter]. J Clin Psychiatry 1994; 55:325-326

    Google Scholar 

  160. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med 1985; 103:228-239

    Google Scholar 

  161. Frankenburg FR, Kando JC, Centorrino F, Gilbert JM: Bladder dysfunction associated with clozapine therapy. J Clin Psychiatry 1996; 57:39-40

    Google Scholar 

  162. Renwick AC, Renwick AG, Flanagan RJ, Ferner RE: Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. Clin Toxicol 2000; 38(3):325-328

    Google Scholar 

  163. Meeker JE, Herrmann PW, Som CW, Reynolds PC: Clozapine tissue concentrations following apparent suicidal overdose of clozaril. J Anal Toxicol 1992; 16:54-56

    Google Scholar 

  164. Worm K, Birgitte K, Steentoft A: Clozapine cases with fatal, toxic or therapeutic concentrations. Int J Legal Med 1993; 106:115-118

    Google Scholar 

  165. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J: Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112:1707-1709

    Google Scholar 

  166. Panagiotis B: Grand mal seizures with liver toxicity in a case of clozapine treatment [Letter]. J Neuropsychiatry Clin Neurosci 1999; 11(1):117-118

    Google Scholar 

  167. Schuster P, Gabriel E, Kufferle B, Strobl G, Karobath M: Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10(4):437-441

    Google Scholar 

  168. Ishii A, Mizoguchi K, Kageoka M, Seno H, Kumazawa T, Suzuki O: Nonfatal suicidal intoxication by clozapine. Clin Toxicol 1997; 35(2):195-197

    Google Scholar 

  169. Mady S, Wax P, Wang D, Goetz C, Hadley C, Love R: Pediatric clozapine intoxication. Am J Emerg Med 1996; 14:462-463

    Google Scholar 

  170. USP DI Drug Information for the Health care professional, Vol 1, 18th edn. Rockville, MD: United States Pharmacopeial Convention; 1998

  171. Physician's desk reference, 53rd edn. Montvale, NJ: Medical Economics; 1999

  172. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW: Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151(6):945

    Google Scholar 

  173. Waldman MD, Safferman AZ: Pregnancy and clozapine. Am J Psychiatry 1993; 150(1):168-169

    Google Scholar 

  174. Lieberman J, Safferman AZ: Clinical profile of clozapine: Adverse reactions and granulocytosis, in clozapine in treatment resistant schizophernia. A Scientific Update. Am J Psychiatry. 1993; 150(1):168-169

    Google Scholar 

  175. Rice DP, Miller LS: The economic burden of schizophernia. Conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius, eds. schizophernia, Vol 1, Handbook of Mental Health Economics and Health Policy. New York: Wiley; 1996: 321-334

    Google Scholar 

  176. Nightangle SA: Approval of clozapine for refractory schizophernia, JAMA 1990; 263:202

    Google Scholar 

  177. Zito JM: Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clin North Am 1998; (21):181-202

    Google Scholar 

  178. Zito JM, Provenzaro G: Pharmaceutical decision making: Pharmaco epidemiology or pharmacoeconomics—Who's in the driver's seat? Psychopharmacol Bull 1996; 31:735-744

    Google Scholar 

  179. Revick DA, Luce BR, Weschler JM, Browns RE, Adler MA: Cost effectiveness of clozapine for treatment resistant schizophernia patients: Hosp Community Psychiatry 1990; 41:850-854

    Google Scholar 

  180. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patient with refractory schizophernia outcome and cost. N Eng J Med 1997; 337:809-815

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, New York

    Mohammad Masud Iqbal

  2. Department of Neurology, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama

    Atiq Rahman

  3. Department of Psychiatry and Behavioral Neurobiology, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama

    Zahid Husain, Syed Zaber Mahmud, William G. Ryan & Jacqueline M. Feldman

Authors
  1. Mohammad Masud Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atiq Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahid Husain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Syed Zaber Mahmud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William G. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jacqueline M. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Masud Iqbal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iqbal, M.M., Rahman, A., Husain, Z. et al. Clozapine: A Clinical Review of Adverse Effects and Management. Ann Clin Psychiatry 15, 33–48 (2003). https://doi.org/10.1023/A:1023228626309

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023228626309

Search

Navigation